Navigation Links
Protalex, Inc. Announces Screening Of First Patients In U.S. For New Trial Of PRTX-100 In Patients With Active Rheumatoid Arthritis
Date:11/8/2012

eating autoimmune and inflammatory diseases, including but not limited to, rheumatoid arthritis. Protalex's lead product, PRTX-100, is formulated with a proprietary highly purified form of Staphylococcal Protein A, and has completed a Phase 1b clinical trial on adult patients with active rheumatoid arthritis in South Africa which demonstrated that PRTX-100 was generally safe and well tolerated at all dose level and at the higher doses, more patients showed improvement in their CDAI (Clinical Disease Activity Index for RA) than did patients at the lower dose or placebo cohorts. PRTX-100 has the ability, at very low concentrations, to bind to and to regulate activation of human B-lymphocytes and macrophages, which mediate inflammation in certain autoimmune diseases.  Laboratory studies indicate that the mechanism involves interaction with specific intracellular signaling pathways.

Forward-Looking Statements

Statements in this press release, including with respect to the outcome of the Phase 1b study described, that are not statements of historical or current fact constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other unknown factors that could cause the Company's actual operating results to be materially different from any historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements that explicitly describe these risks and uncertainties, readers are urged to consider statements that contain terms such as "believes," "belief," "expects," "expect," "intends," "intend," "anticipate," "anticipates," "plans," "plan," to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's filings with Securities and Exchange Commission.

Media Contact:
Mackenzie Mills
SpecO
'/>"/>

SOURCE Protalex, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Harwood Feffer LLP Announces Investigation of DUSA Pharmaceuticals, Inc.
2. ActiveCare Announces Record Revenue For Quarter Ending June 30, 2012
3. Echo Therapeutics Announces Third Quarter 2012 Financial Results
4. Concord Medical Announces Change to Third Quarter Financial Results Date to November 20, 2012
5. Winner Medical Announces Mailing of Definitive Proxy Materials for Special Meeting of Shareholders
6. Genoa Pharmaceuticals announces $1.2M Financing
7. Genomic Health Announces Third Quarter 2012 Financial Results and Business Progress
8. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
9. Life Technologies Announces Next-Gen Digital PCR Instrument Designed for Widespread Adoption
10. Blue Belt Technologies Announces First United Kingdom-Based NavioPFS Unicondylar Knee Replacement Surgery
11. IRIDEX Announces Tender Offer to Purchase up to 487,500 Shares of its Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... NEW YORK , Jan. 15, ... new market research report is available ... Global Markets and Technologies for ... on Routes of Administration ...
(Date:1/15/2014)... 2014  A novel wearable injector slightly larger than an Oreo ... to self-inject prescription drugs in the large doses required to ... autoimmune deficiencies, and genetic disorders.  An emerging ... 2018, according to analysts.   Many of these drugs will require ...
(Date:1/14/2014)... AUSTIN, Texas , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... report results for the fourth quarter of 2013 on Monday, ... scheduled for release after the close of trading. ... a conference call to discuss the operating highlights and financial ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... Inc. (NASDAQ: QCOR ) today announced ... to its Board of Directors.  Dr. Whitcup is ... Chief Scientific Officer at Allergan, Inc.  In that ... research and development organization, including medical affairs, drug ...
... Feb. 16, 2012 OPKO Health, Inc. and ChromaDex ... a strategic alliance pursuant to which ChromaDex has licensed ... health care technologies for distribution and business development throughout ... commercialized are BluScience™ ( www.bluscience.com ), ChromaDex,s ...
Cached Medicine Technology:Questcor Pharmaceuticals Appoints Scott M. Whitcup, M.D., to Board of Directors 2Questcor Pharmaceuticals Appoints Scott M. Whitcup, M.D., to Board of Directors 3Questcor Pharmaceuticals Appoints Scott M. Whitcup, M.D., to Board of Directors 4OPKO Health, Inc. Invests in ChromaDex® Corp. 2OPKO Health, Inc. Invests in ChromaDex® Corp. 3OPKO Health, Inc. Invests in ChromaDex® Corp. 4OPKO Health, Inc. Invests in ChromaDex® Corp. 5
(Date:4/18/2014)... LEXINGTON, Ky. (April 21, 2014) -- A group ... of Medicine and the Sanders-Brown Center on Aging ... on depression and neuropsychological function in Parkinson,s disease ... Psychiatry Research , the study, which assessed cognitive ... found that the dopamine replacement therapy commonly used ...
(Date:4/18/2014)... researchers have been awarded two-year grants for their work ... month. Of the 110 initial submissions to the new ... only four projects were funded, three of which are ... M.D., Ph.D.; G. William Wong, Ph.D.; and Elias Zambidis, ... oncology, will use his $500,000 proof of principle grant ...
(Date:4/18/2014)... new study in the American Journal of Preventive ... reveals a recurring pattern that could be leveraged to ... San Diego State University, the Santa Fe Institute, Johns ... searches (searches that included the term healthy and were ... from 2005 to 2012. They found that on average, ...
(Date:4/17/2014)... in non-cancerous prostate tissue may have nearly twice the ... no inflammation, according to results of a new study ... Center. , The link between persistent inflammation and cancer ... cancer those with a Gleason score between 7 ... aggressive and rapidly growing prostate cancers. , "What we,ve ...
(Date:4/17/2014)... published today in PLOS Pathogens , children who ... common can mount an immune response to infection with ... bouts of high fever and illness and partially control ... findings may help researchers develop future interventions that prevent ... , Each year, approximately 200 million cases of malaria ...
Breaking Medicine News(10 mins):Health News:Treating depression in PD patients: New research 2Health News:New research shows people are thinking about their health early in the week 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study sheds light on how the immune system protects children from malaria 2
... Alan Mozes HealthDay Reporter , MONDAY, Sept. 19 ... common, non-infectious diseases -- cancer, diabetes, heart disease, lung disease ... million in treatment costs and lost wages. ... Burden of Non-communicable Diseases," released by the World Economic Forum ...
... pioneered a new combination treatment for prostate cancer. The ... will now be tested for efficacy in a second phase. ... and aggressive form of prostate cancer which has spread to ... developed. It combines traditional chemotherapy treatments with two doses ...
... Massachusetts health care reform designed to bolster employer-based insurance ... unable to afford it, the uninsured in Massachusetts remain ... by researchers at Harvard Medical School just published online ... The 2006 comprehensive health care reform was designed ...
... 17 (HealthDay News) -- ,Paralyzed veterans who learned to ... new study suggests. Researchers brought 10 paralyzed veterans ... May for a four-day scuba certification course. Before ... psychological tests, measuring muscle spasticity, motor control and sensitivity ...
... 16 (HealthDay News) -- People who carry a certain ... a lower five-year survival rate after coronary artery bypass ... to better treat and ensure the survival of these ... from Duke University Medical Center in Durham, N.C. ...
... September 16, 2011 Researchers have shown for the first ... by binding to and rendering inert protein p53, a known ... Texas Medical Branch may lead to treatments for a range ... appears in the current print issue of the Journal ...
Cached Medicine News:Health News:Global Toll of 'Non-Communicable Diseases' -- $47 Trillion by 2030 2Health News:Global Toll of 'Non-Communicable Diseases' -- $47 Trillion by 2030 3Health News:Global Toll of 'Non-Communicable Diseases' -- $47 Trillion by 2030 4Health News:Queen's pioneers prostate cancer breakthrough 2Health News:Uninsured patients in Mass. still mainly the working poor, despite state's health reform 2Health News:Uninsured patients in Mass. still mainly the working poor, despite state's health reform 3Health News:Scuba Diving May Help Paralyzed Vets 2Health News:Gene Variant May Raise Death Risk After Heart Bypass 2Health News:Researchers identify potential molecular target to prevent growth of cancer cells 2
... can code the charge while completing a chart ... away from office, both directly feeding the charge ... Encounter Form/Superbill, data entry can be done with ... payments are posted by reflecting open item charges, ...
The HearTwave system is the original stand-alone Microvolt T-Wave Alternans (MTWA) testing platform....
... that a second mirror adds, then you may ... features the same 1.5x magnification as the G-1 ... and 64 respectively. Available in standard (flange) or ... "Flanged" model for laser use. Provides ...
... The AFX (Air Fluid ... image lens designed for use ... addition to its use as ... lens, the low profile and ...
Medicine Products: